Analysis of Fas and Fas ligand expression and function in lung cancer cell lines.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  European Journal of Cancer

• Publication date

  2000-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0959-8049(99)00332-9PMID 10738132
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Induction of interleukin-8 secretion and apoptosis in bronchiolar epithelial cells by Fas ligation.

  1999cited by this paper
• Expression of FAS (CD95/APO‐1) and FAS ligand in lung cancer, its prognostic and predictive relevance

  1999cited by this paper
• Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas.

  1998cited by this paper
• Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis.

  1998cited by this paper
• FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation.

  1998cited by this paper
• Fas receptor is expressed in human lung squamous cell carcinomas, whereas bcl-2 and apoptosis are not pronounced: a preliminary report.

  1997cited by this paper
• Human lung carcinomas express Fas ligand.

  1997cited by this paper
• Membrane Fas Ligand Kills Human Peripheral Blood T Lymphocytes, and Soluble Fas Ligand Blocks the Killing

  1997cited by this paper
• Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions.

  1997cited by this paper
• Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells.

  1997cited by this paper
• Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance.

  1997cited by this paper
• Fas-Fas ligand-based interactions between tumor cells and tumor-specific cytotoxic T lymphocytes: a lethal two-way street.

  1997cited by this paper
• The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells.

  1997cited by this paper
• Agonist antibody and Fas ligand mediate different sensitivity to death in the signaling pathways of Fas and cytoplasmic mutants

  1997cited by this paper
• Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back.

  1997cited by this paper
• Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53.

  1997cited by this paper
• Chemotherapy-induced apoptosis.

  1997cited by this paper
• Fas antigen expression and its relationship with apoptosis in human hepatocellular carcinoma and noncancerous tissues.

  1996cited by this paper
• The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand

  1996cited by this paper
• Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cells

  1996cited by this paper
• Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion?

  1996cited by this paper
• Expansion or elimination of B cells in vivo: dual roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor.

  1996cited by this paper
• Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape

  1996cited by this paper
• A mitochondrial membrane protein defined by a novel monoclonal antibody is preferentially detected in apoptotic cells.

  1996cited by this paper
• Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)

  1995cited by this paper
• The Fas death factor

  1995cited by this paper
• A role for CD95 ligand in preventing graft rejection

  1995cited by this paper
• Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege

  1995cited by this paper
• Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines.

  1994cited by this paper
• Expression of APO‐1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium

  1994cited by this paper
• Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness.

  1994cited by this paper
• Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells.

  1993cited by this paper
• Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family.

  1993cited by this paper
• Apoptosis Biochemical events and relevance to cancer chemotherapy

  1992cited by this paper
• A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer.

  1986cited by this paper
• Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

  1983cited by this paper

• Apoptosis-Inducing TNF Superfamily Ligands for Cancer Therapy

  2021cites this paper
• Synthesis, biological evaluation and molecular dynamics simulation studies of novel diphenyl ethers.

  2019cites this paper
• Expression of long non-coding RNAs (lncRNAs) has been dysregulated in non-small cell lung cancer tissues

  2019cites this paper
• Apoptosis of tumor-infiltrating T lymphocytes: a new immune checkpoint mechanism

  2018cites this paper
• Pigment Epithelial-derived Factor (PEDF)-triggered Lung Cancer Cell Apoptosis Relies on p53 Protein-driven Fas Ligand (Fas-L) Up-regulation and Fas Protein Cell Surface Translocation*

  2014cites this paper
• Stellera chamaejasme L. extract induces apoptosis of human lung cancer cells via activation of the death receptor-dependent pathway

  2012cites this paper
• Lung carcinomas do not induce T-cell apoptosis via the Fas/Fas ligand pathway but down-regulate CD3 epsilon expression

  2008cites this paper
• The variation in Fas localization and the changes in Fas expression level upon stimulation with growth factors.

  2007cites this paper
• Expression of Fas and FasL in human neuroblastoma and its clinical significance

  2007cites this paper
• An improved Tet-On regulatable FasL-adenovirus vector system for lung cancer therapy

  2006cites this paper
• Anti-gastric cancer active immunity induced by FasL/B7-1 genes modified tumor cells

  2005cites this paper
• Prognostic significance of Bax and Fas ligand in erionite and asbestos induced Turkish malignant pleural mesothelioma.

  2005cites this paper
• Indomethacin-induced activation of the death receptor-mediated apoptosis pathway circumvents acquired doxorubicin resistance in SCLC cells

  2005cites this paper
• Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma

  2003cites this paper
• Cisplatin augments cytotoxic T-lymphocyte-mediated antitumor immunity in poorly immunogenic murine lung cancer.

  2003cites this paper
• Apoptozis Mekanizmaları: Tümör Gelişiminde Fas-FasL Bağımlı Apoptozis

  2003cites this paper
• Active, specific immunotherapy for lung cancer: hurdles and strategies using genetic modification.

  2003cites this paper
• Soluble Fas in malignant pleural effusion and its expression in lung cancer cells

  2003cites this paper
• Analysis of cytotoxic T lymphocytes and Fas/FasL in Japanese patients with non-small cell lung cancer associated with HLA-A2

  2002cites this paper
• Cisplatin induces apoptosis in LLC-PK1 cells via activation of mitochondrial pathways.

  2002cites this paper
• Induction of apoptosis in malignant pleural mesothelioma cells by activation of the Fas (Apo-1/CD95) death-signal pathway.

  2002cites this paper
• TRAIL, Fasl and a blocking anti‐DR5 antibody augment paclitaxel‐induced apoptosis in human non‐small‐cell lung cancer

  2002cites this paper
• Defining CD95 as a tumor suppressor gene

  2000cites this paper